Semaglutide vs Tirzepatide: Which is Better for Weight Loss?
Head-to-head comparison of semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound): mechanisms, clinical trial weight loss data, side effects, dosing, and cost.
Semaglutide
Ozempic
FDA ApprovedTirzepatide
Mounjaro
FDA ApprovedSemaglutide
An FDA-approved GLP-1 receptor agonist that produces significant weight loss (average 14.9% body weight in clinical trials). One of the most clinically validated weight loss peptides available.
Tirzepatide
A dual GLP-1 and GIP receptor agonist representing the next generation of metabolic peptides. Achieves greater weight loss than semaglutide with average reductions of 20-22.5% body weight.
Common Questions
Q: Which causes more weight loss?
See the full comparison in our detailed guide.
Q: Which has fewer side effects?
See the full comparison in our detailed guide.
Q: Which is FDA-approved?
See the full comparison in our detailed guide.
Q: What is the mechanism difference?
See the full comparison in our detailed guide.
Q: Which is more expensive?
See the full comparison in our detailed guide.
Our Verdict
Winner: Tirzepatide (for weight loss)
Tirzepatide consistently achieves 5-7 percentage points more weight loss than semaglutide in clinical trials (20-22% vs 14.9% body weight). However, semaglutide has a longer safety track record and is currently less expensive. For maximum weight loss efficacy, tirzepatide wins. For patients with established GLP-1 tolerance or cost constraints, semaglutide remains highly effective.